Verteporfin photodynamic therapy for neovascular age-related ...

More documents

Recommendations

Info

86 References49. Guymer RH, Chiu AW, Lim L, Baird PN. HMG CoA reductase inhibitors (statins): do theyhave a role in age-related macular degeneration? Surv Ophthalmol 2005;50:194–206.50. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-relatedmacular degeneration: pooled findings from three continents. Ophthalmology 2001;108:697–704.51. Doris H, Hart PM, Chakravarthy U, McCleland J, Stevenson M, Hudson C, et al.Relation between macular morphology and visual function in patients with choroidalneovascularisation of age related macular degeneration. Br J Ophthalmol 2001;85:184–8.52. Hendy J, Fulop N, Reeves BC, Hutchings A, Collin S. Implementing the NationalProgramme for Information Technology: a qualitative study of progress in acute trusts. BMJ2007;334:1360–4.53. British Medical Association and Royal Pharmaceutical Society of Great Britain. Britishnational formulary. No. 57, March 2009. London: BMA and RPS; 2009.54. Department of Health. NHS Reference Costs 2002. Appendix 1E. National Schedule ofReference Costs: NHS Trust Outpatient HRG Data. Ophthalmology HRG Label. London:Department of Health; 2002. pp. 136.55. Curtis L. Unit costs of health and social care. University of Kent, Canterbury: Personal SocialService Research Unit; 2008. pp. 35–178.56. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model inhealth econometrics. J Health Econ 1998;17:247–81.57. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysisusing Monte Carlo simulation: a practical approach. Med Decis Making 1985;5:157–77.58. Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating nonrandomisedintervention studies. Health Technol Assess 2003;7(27).59. Wormald R, Evans JR, Smeeth LL, Henshaw KS. Photodynamic therapy for neovascular agerelatedmacular degeneration. Cochrane Database Syst Rev 2007, Issue 3. Art. No. CD002030.DOI: 10.1002/14651858.CD002030.pub3.60. El Mallah MK, Chakravarthy U, Hart PM. Amblyopia: is visual loss permanent? Br JOphthalmol 2000;84:952–6.61. Swets J, Tanner WP Jr, Birdsall TG. Decision processes in perception. Psychol Rev1961;68:301–40.62. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. Apragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trialdesigners. J Clin Epidemiol 2009;62:464–75.63. Zwarenstein MJ, Treweek S. What kind of randomized trials do we need? CMAJ2009;180:998–1000.64. Espallargues M, Czoski-Murray CJ, Bansback NJ, Carlton J, Lewis GM, Hughes LA, et al. Theimpact of age-related macular degeneration on health status utility values. Invest OphthalmolVis Sci 2005;46:4016–23.65. Submacular Surgery Trials Research Group. Evaluation of minimum clinically meaningfulchanges in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ)SST Report Number 19. Ophthalmic Epidemiol 2007;14:205–15.66. Bansback N, Czoski-Murray C, Carlton J, Lewis G, Hughes L, Espallargues M, et al.Determinants of health related quality of life and health state utility in patients with age
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 687related macular degeneration: the association of contrast sensitivity and visual acuity. QualLife Res 2007;16:533–43.67. Health Utilities Inc. Health Utilities Index Mark 3; 2008. URL: www.healthutilities.com/hui3.htm (accessed 30 November 2010).68. Chakravarthy U, Stevenson M. Self-reported visual functioning and quality of life in agerelatedmacular degeneration. Curr Opin Ophthalmol 2005;16:179–83.69. World Health Organization. Constitution of the World Health Organization. Basic Documents.45th edn. Supplement, October 2006. URL: www.who.int/governance/eb/who_constitution_en.pdf (accessed 30 November 2010).70. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and the SF-6Dacross seven patient groups. Health Econ 2004;13:873–84.71. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, et al. Multiattributeand single-attribute utility functions for the Health Utilities Index Mark 3 system. Med Care2002;40:113–28.72. Stevens KJ, McCabe CJ, Brazier JE. Mapping between Visual Analogue Scale and StandardGamble data: results from the UK Health Utilities Index 2 valuation survey. Health Econ2007;15:527–33.73. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab forneovascular age-related macular degeneration. N Engl J Med 2006;355:1419–31.74. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumabversus verteporfin for neovascular age-related macular degeneration. N Engl J Med2006;355:1432–44.75. Browne J, Jamieson L, Lewsey J, Van der Meulen J, Black N, Cairns J, et al. Patient ReportedOutcome Measures (PROMs) in elective surgery. Report to the Department of Health; 2007.URL: www.lshtm.ac.uk/hsru/research/PROMs-Report-12-Dec-07.pdf (accessed 4 October2009).76. Griffin SC, Barber JA, Manca A, Sculpher MJ, Thompson SG, Buxton MJ, et al. Costeffectiveness of clinically appropriate decisions on alternative treatments for angina pectoris:prospective observational study. BMJ 2007;334;624.77. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapywith verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol2004;88:1107–12.78. Fletcher EC, Lade RJ, Adewoyin T, Chong NV. Computerized model of cost-utility analysisfor treatment of age-related macular degeneration. Ophthalmology 2008;115:2192–8.79. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness ofphotodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondaryto age-related macular degeneration. Ophthalmology 2001;108:2051–9.80. Coleman AL, Yu F. Eye-related Medicare costs for patients with age-related maculardegeneration from 1995 to 1999. Ophthalmology 2008;115:18–25.81. Smiddy WE. Relative cost of a line of vision in age-related macular degeneration.Ophthalmology 2007;114:847–54.82. Birchall W. Minimising the impact of visual impairment: training in use of low vision aids isimportant. BMJ 1999;319:707.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
Page 5 and 6:
DOI: 10.3310/hta16060Health Technol
Page 12 and 13:
xExecutive summaryretreat on criter
Page 14 and 15:
xiiExecutive summaryof data, with i
Page 16 and 17:
2 Introductionon-going or new clini
Page 18 and 19:
4 Introductionof VPDT in routine cl
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31:
Page 34 and 35:
20 Key changes to the protocolThese
Page 36 and 37:
22 Key changes to the protocolCentr
Page 38 and 39:
24 Key changes to the protocolADVER
Page 40 and 41:
26 Key changes to the protocolPlan
Page 42 and 43:
28 Key changes to the protocolClass
Page 44 and 45:
30 Key changes to the protocolFor i
Page 46 and 47:
32 Key changes to the protocolIn ad
Page 48 and 49:
34 Key changes to the protocolsites
Page 52 and 53: 38 Results (1) - study cohortTABLE
Page 60 and 61: 46 Results (2) - objectives A, B, C
Page 69 and 70: DOI: 10.3310/hta16060Health Technol
Page 77: DOI: 10.3310/hta16060Health Technol
Page 80 and 81: 66 Discussion of resultsStrengths a
Page 82 and 83: 68 Discussion of resultsThe VPDT st
Page 84 and 85: 70 Discussion of resultsOur analyse
Page 86 and 87: 72 Discussion of resultsA further c
Page 88 and 89: 74 Discussion of resultsVPDT. It is
Page 95: DOI: 10.3310/hta16060Health Technol
Page 98 and 99: 84 References16. Stelmack J. Qualit
Page 102 and 103: 88 References83. Margrain TH. Minim
Page 104 and 105: 90 Appendix 1THE VERTEPORFIN PHOTOD
Page 106 and 107: 92 Appendix 11. Overview of Manual
Page 108 and 109: 94 Appendix 1And, if also collectin
Page 110 and 111: 96 Appendix 1more patients in the v
Page 112 and 113: 98 Appendix 12.4 Limitations of the
Page 114 and 115: 100 Appendix 1Box 2 Key advantages
Page 116 and 117: 102 Appendix 14. Study population4.
Page 118 and 119: 104 Appendix 15. Recruitment to the
Page 120 and 121: 106 Appendix 16. Background data co
Page 122 and 123: 108 Appendix 1Table 1: Schedule of
Page 124 and 125: 110 Appendix 1The Verteporfin Photo
Page 126 and 127: 112 Appendix 1• Additional clinic
Page 128 and 129: 114 Appendix 18. Recording adverse
Page 130 and 131: 116 Appendix 1level of benefit from
Page 132 and 133: 118 Appendix 1• comparison of num
Page 134 and 135: 120 Appendix 110.6 Sub-group analys
Page 136 and 137: 122 Appendix 112. Data issues12.1 D
Page 138 and 139: 124 Appendix 113. Organisation13.1
Page 140 and 141: 126 Appendix 114. References[1] Ref
Page 142 and 143: 128 Appendix 1Barnes RM, Gee L, Tay
Page 144 and 145: 130 Appendix 1Appendix 1: Classifyi
Page 146 and 147: 132 Appendix 1Liverpool re-treatmen
Page 148 and 149: 134 Appendix 1Service StructurePlea
Page 150 and 151:
136 Appendix 1Has your photographer
Page 152 and 153:
138 Appendix 1There are many differ
Page 154 and 155:
140 Appendix 1testing on vision tes
Page 156 and 157:
142 Appendix 1something to do with
Page 158 and 159:
144 Appendix 1College of Ophthalmol
Page 160 and 161:
146 Appendix 1Appendix 5:Protocol f
Page 162 and 163:
148 Appendix 16.2 Subjective Refrac
Page 164 and 165:
150 Appendix 1• The patient shoul
Page 166 and 167:
152 Appendix 1Appendix 6:Protocol f
Page 168 and 169:
154 Appendix 18. It is customary to
Page 170 and 171:
156 Appendix 1Early or Transit Phas
Page 172 and 173:
158 Appendix 1
Page 174 and 175:
160 Appendix 1---------------------
Page 176 and 177:
162 Appendix 1---------------------
Page 178 and 179:
164 Appendix 1---------------------
Page 180 and 181:
166 Appendix 1Appendix 9:Site imple
Page 182 and 183:
168 Appendix 1Option 2 - units inte
Page 184 and 185:
170 Appendix 1Dos and Don’tsDosDo
Page 186 and 187:
172 Appendix 1Resource use question
Page 188 and 189:
174 Appendix 1Appendix 11: Recommen
Page 190 and 191:
176 Appendix 1ADVERSE REACTION AND
Page 192 and 193:
178 Appendix 1acute Trust; note tha
Page 194 and 195:
180 Appendix 1Ophthalmologistrespon
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203:
Page 206 and 207:
192 Appendix 3manufacturer’s pers
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 216:
FeedbackThe HTA programme and the a
show all

Verteporfin photodynamic therapy for neovascular age-related ...

Create successful ePaper yourself

Delete template?

Save as template?